WO2004093860A1 - Inhibiteurs de proteinase de coronavirus apparente au virus du sras - Google Patents

Inhibiteurs de proteinase de coronavirus apparente au virus du sras Download PDF

Info

Publication number
WO2004093860A1
WO2004093860A1 PCT/IB2004/001307 IB2004001307W WO2004093860A1 WO 2004093860 A1 WO2004093860 A1 WO 2004093860A1 IB 2004001307 W IB2004001307 W IB 2004001307W WO 2004093860 A1 WO2004093860 A1 WO 2004093860A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
cycloalkyl
heterocycloalkyl
independently
Prior art date
Application number
PCT/IB2004/001307
Other languages
English (en)
Inventor
Shella Ann Fuhrman
David Allan Matthews
Amy Karen Patick
Paul Abraham Rejto
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of WO2004093860A1 publication Critical patent/WO2004093860A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à des procédés d'inhibition de l'activité de réplication virale d'un coronavirus apparenté au virus du SRAS, consistant à mettre une protéase de coronavirus apparenté au virus du SRAS en contact avec une quantité thérapeutique efficace d'un inhibiteur de protéase de rhinovirus, ainsi qu'à des compositions associées.
PCT/IB2004/001307 2003-04-21 2004-04-13 Inhibiteurs de proteinase de coronavirus apparente au virus du sras WO2004093860A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US46455603P 2003-04-21 2003-04-21
US60/464,556 2003-04-21
US46819703P 2003-05-05 2003-05-05
US60/468,197 2003-05-05
US46850403P 2003-05-06 2003-05-06
US60/468,504 2003-05-06
US46906503P 2003-05-07 2003-05-07
US60/469,065 2003-05-07

Publications (1)

Publication Number Publication Date
WO2004093860A1 true WO2004093860A1 (fr) 2004-11-04

Family

ID=33314445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001307 WO2004093860A1 (fr) 2003-04-21 2004-04-13 Inhibiteurs de proteinase de coronavirus apparente au virus du sras

Country Status (2)

Country Link
TW (1) TW200424175A (fr)
WO (1) WO2004093860A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1704142A1 (fr) * 2003-12-31 2006-09-27 Taigen Biotechnology Inhibiteurs de la protease
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2021202735A1 (fr) * 2020-03-31 2021-10-07 Diffusion Pharmaceuticals Llc Utilisation de composés d'amélioration de la diffusion pour le traitement d'une maladie respiratoire induite par des virus et des bactéries
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
CN113773259A (zh) * 2021-07-14 2021-12-10 上海药明康德新药开发有限公司 病毒主蛋白酶抑制剂及其制备方法和用途
WO2022040186A1 (fr) * 2020-08-18 2022-02-24 Anixa Biosciences, Inc. Inhibiteurs de cystéine protéase mpro
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022156692A1 (fr) * 2021-01-22 2022-07-28 中国人民解放军军事科学院军事医学研究院 Inhibiteur peptidique cyclique de protéase virale, son procédé de préparation et son application dans des médicaments antiviraux

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283831A1 (fr) * 2021-07-14 2023-01-19 上海药明康德新药开发有限公司 Inhibiteur de protéase principale virale, son procédé de préparation et son utilisation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020371A (en) * 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US6331554B1 (en) * 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
US6369226B1 (en) * 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
US6514997B2 (en) * 1999-12-03 2003-02-04 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6531452B1 (en) * 1998-04-30 2003-03-11 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6534530B1 (en) * 1999-08-04 2003-03-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US20030203887A1 (en) * 1995-06-02 2003-10-30 Mcw Research Foundation, Inc., Methods for in vivo reduction of free radical levels and compostions useful therefor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203887A1 (en) * 1995-06-02 2003-10-30 Mcw Research Foundation, Inc., Methods for in vivo reduction of free radical levels and compostions useful therefor
US6020371A (en) * 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US6331554B1 (en) * 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
US6531452B1 (en) * 1998-04-30 2003-03-11 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6369226B1 (en) * 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
US6534530B1 (en) * 1999-08-04 2003-03-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6514997B2 (en) * 1999-12-03 2003-02-04 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANAND KANCHAN ET AL: "Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5626, 13 June 2003 (2003-06-13), pages 1763 - 1767, XP002291115, ISSN: 0036-8075 *
ELLIS C.: "A common cure for SARS ?.", NATURE REVIEWS DRUG DISCOVERY, 2/7 (509). REFS: 1 ISSN: 1474-1776 CODEN: NRDDAG, 2003, XP008035035 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1704142A4 (fr) * 2003-12-31 2008-08-20 Taigen Biotechnology Co Ltd Inhibiteurs de la protease
EP1704142A1 (fr) * 2003-12-31 2006-09-27 Taigen Biotechnology Inhibiteurs de la protease
WO2021202735A1 (fr) * 2020-03-31 2021-10-07 Diffusion Pharmaceuticals Llc Utilisation de composés d'amélioration de la diffusion pour le traitement d'une maladie respiratoire induite par des virus et des bactéries
US11472793B2 (en) 2020-04-17 2022-10-18 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11312704B2 (en) 2020-04-17 2022-04-26 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11524940B1 (en) 2020-06-09 2022-12-13 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2022040186A1 (fr) * 2020-08-18 2022-02-24 Anixa Biosciences, Inc. Inhibiteurs de cystéine protéase mpro
US11452711B2 (en) 2020-09-03 2022-09-27 Pfizer Inc. Nitrile-containing antiviral compounds
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US11541034B2 (en) 2020-09-03 2023-01-03 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022156692A1 (fr) * 2021-01-22 2022-07-28 中国人民解放军军事科学院军事医学研究院 Inhibiteur peptidique cyclique de protéase virale, son procédé de préparation et son application dans des médicaments antiviraux
CN113773259A (zh) * 2021-07-14 2021-12-10 上海药明康德新药开发有限公司 病毒主蛋白酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
TW200424175A (en) 2004-11-16

Similar Documents

Publication Publication Date Title
US20060014821A1 (en) Inhibitors of SARS 3C like protease
KR20220045251A (ko) 니트릴-함유 항바이러스 화합물
WO2004073599A2 (fr) Inhibiteurs du virus de l'hepatite c, compositions et traitements utilisant ces inhibiteurs
CN101932325B (zh) Ido抑制剂
WO2021205296A1 (fr) Méthode de traitement de la covid-19
WO1998035675A1 (fr) Procede d'utilisation de composes de sulfamides neurotrophiques
CA3174069A1 (fr) Procedes d'inhibition de la replication du sras-cov-2 et de traitement de la maladie a coronavirus 2019
JP2015051985A (ja) カテプシンｂの阻害剤
Vankadara et al. A warhead substitution study on the coronavirus main protease inhibitor nirmatrelvir
Shih et al. Selective human enterovirus and rhinovirus inhibitors: An overview of capsid‐binding and protease‐inhibiting molecules
WO2004093860A1 (fr) Inhibiteurs de proteinase de coronavirus apparente au virus du sras
WO2005043118A2 (fr) Methode de decouverte de medicament
CN105085429A (zh) 芳杂环类衍生物及其在药物上的应用
Ojima et al. Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ
WO2021205290A1 (fr) Composés et procédé de traitement de la covid-19
Paul et al. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors
Wang et al. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate
US20040235952A1 (en) Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
KR20240055745A (ko) 코로나바이러스 억제제
TW202304888A (zh) 醚連接之抗病毒化合物
JP2023539428A (ja) ウイルス感染症を処置するためのニューロピリンおよびアンジオテンシン変換酵素２融合ペプチド
CN114699419A (zh) PLpro蛋白抑制剂在治疗或预防新型冠状病毒感染的药物中的应用
KR20100066142A (ko) 3,5-디아릴-4,5-디히드로 피라졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 피코르나바이러스 및 코로나바이러스에 의해 유발되는 질환의 예방 또는 치료용 조성물
Ivashchenko et al. Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors
Flury et al. Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase